AEterna Zentaris is a biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Co.'s lead product, Macrilen (macimorelin) is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency. Macrilen is marketed in the United States through a license and assignment agreement with Novo Nordisk A/S. Co. is also pursuing the development of macimorelin for the diagnosis of child-onset growth hormone deficiency. Co.'s principal focus is on the commercialization of Macrilen and it does not have any other approved products. The AEZS stock yearly return is shown above.
The yearly return on the AEZS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AEZS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|